Diflucan 150 mg (Fluconazole) and Suvorexant: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Moderate CYP3A inhibition may increase suvorexant exposure.
Clinical significance and safety
Diflucan 150 mg (Fluconazole) and Suvorexant: Moderate CYP3A inhibition may increase suvorexant exposure. Changes in exposure can affect tolerability or treatment response. The prescriber must check the exact inhibitor, formulation, dose and timing against the cited product information; doses should not be adjusted without that review. The suvorexant instruction for a moderate CYP3A inhibitor differs from its instruction for a strong inhibitor; they must not be treated as interchangeable. Ask a pharmacist or prescriber to review the full medicine list before adding or changing treatment.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.